Multiple myeloma Trials in Katowice, Poland
Conditions / Multiple myeloma / Katowice, Poland
Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05552222 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | RECRUITING | PHASE3 |
| NCT05083169 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02412878 | Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma | COMPLETED | PHASE3 |
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | RECRUITING | — |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | RECRUITING | PHASE3 |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE2 |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | RECRUITING | PHASE3 |
| NCT05317416 | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | ACTIVE_NOT_RECRUITING | — |
| NCT02136134 | Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | COMPLETED | PHASE3 |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma | COMPLETED | PHASE3 |